Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

IXICO CEO discusses significance of two major neuroimaging contract wins

4:25
 
Share
 

Manage episode 500064823 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s latest contract wins in two key therapeutic areas — Alzheimer’s disease and Friedreich’s Ataxia. Goorden said the first deal is a phase 1 international trial in Alzheimer’s disease with a major pharmaceutical company, reinforcing IXICO’s aim to deepen its involvement in this therapeutic area. “This is another testament to that happening as we speak,” he noted, adding that successful early-stage results could lead to further work in phase 2 and beyond. The second contract is a phase 1b trial in Friedreich’s Ataxia, a rare neurodegenerative disease affecting about one in 50,000 people. IXICO will provide advanced imaging services, including MRI and DTI reads, over a six-year period for a US biotech client. Goorden emphasised that, despite its rarity, there is a “dire need for a solution” for patients, making this collaboration particularly meaningful. Both deals align with IXICO’s 'innovate, lead, scale' strategy, demonstrating its capability to deliver sophisticated imaging solutions and maintain a presence in targeted disease ecosystems. For more updates from IXICO PLC and other companies, visit Proactive’s YouTube channel, give this video a like, subscribe, and turn on notifications so you don’t miss future content. #IXICOPLC #AlzheimersResearch #FriedreichsAtaxia #ClinicalTrials #NeurodegenerativeDiseases #CNSResearch #BiotechNews #MRIImaging #DrugDevelopment #RareDiseaseResearch
  continue reading

614 episodes

Artwork
iconShare
 
Manage episode 500064823 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s latest contract wins in two key therapeutic areas — Alzheimer’s disease and Friedreich’s Ataxia. Goorden said the first deal is a phase 1 international trial in Alzheimer’s disease with a major pharmaceutical company, reinforcing IXICO’s aim to deepen its involvement in this therapeutic area. “This is another testament to that happening as we speak,” he noted, adding that successful early-stage results could lead to further work in phase 2 and beyond. The second contract is a phase 1b trial in Friedreich’s Ataxia, a rare neurodegenerative disease affecting about one in 50,000 people. IXICO will provide advanced imaging services, including MRI and DTI reads, over a six-year period for a US biotech client. Goorden emphasised that, despite its rarity, there is a “dire need for a solution” for patients, making this collaboration particularly meaningful. Both deals align with IXICO’s 'innovate, lead, scale' strategy, demonstrating its capability to deliver sophisticated imaging solutions and maintain a presence in targeted disease ecosystems. For more updates from IXICO PLC and other companies, visit Proactive’s YouTube channel, give this video a like, subscribe, and turn on notifications so you don’t miss future content. #IXICOPLC #AlzheimersResearch #FriedreichsAtaxia #ClinicalTrials #NeurodegenerativeDiseases #CNSResearch #BiotechNews #MRIImaging #DrugDevelopment #RareDiseaseResearch
  continue reading

614 episodes

Tất cả các tập

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play